In a single-blinded study, two groups of 10 healthy subjects were given cephapirin or cephalothin by continuous intravenous infusion for 5 days, 0.5 g every 6 hr for the first day and then 1.0 g every 6 hr for 4 days. Eight of the cephalothin subjects and two of the cephapirin subjects developed phlebitis. Phlebitis was more severe in the cephalothin group and developed more rapidly, necessitating vein changes six times more often than in the cephapirin group. The less irritating properties of cephapirin demonstrated in this study indicate it may be the more useful cephalosporin analogue for intravenous therapy.
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Of the two parenteral cephalosporins available, cephalothin is usually preferred for the treatment of infections requiring high intravenous doses because cephaloridine in doses over 2 g daily may be nephrotoxic (Loridine® package insert, Eli Lilly & Co. For the first 24 hr, 0.5-g amounts of the drugs in 250 ml of normal saline were infused over each 6-hr period; then the dosage was raised to 1.0 g in 250 ml every 6 hr for the remaining 4 days. During each 6-hr period, flow rates were kept as uniform as possible. To simulate the clinical situation, 21-gauge needles and an intravenous infusion apparatus commonly used in hospitals (Metriset) were employed.
The physician in residence at the institution started all infusions and kept them going at a constant rate around the clock for 5 days with the aid of technicians. He examined infusion sites at least once every day and graded phlebitis as absent, mild, moderate, or severe, depending on the degree of any swelling, redness, tenderness, discoloration, induration, or sclerosing of veins. The subject's comments regarding pain or discomfort were elicited without the use of leading questions. The physician decided when infusion sites should be changed.
Because cephapirin went into solution more rapidly on reconstitution and was usually a darker color than cephalothin, it was not possible to blind the physician and paramedical staff as to drug identity. Subjects, however, were kept unaware of which drug they were receiving, and care was taken not to influence their subjective reactions during the study.
RESULTS
The incidence and severity of phlebitis were greater with cephalothin and irritation developed more rapidly. Eight of 10 subjects given cephalothin and 2 of 10 subjects given cephapirin developed phlebitis, necessitating 13 vein changes in the cephalothin group compared to 2 in the cephapirin group (Tables 1 and 2 ). The difference in the number of patients who developed phlebitis in the two groups is statistically significant at the 0.05 level of confidence (chi-square test).
One subject in the cephalothin group had thrombophlebitis, distinguished from phlebitis VOL. 2, 1972 PHLEBITIS CAUSED BY CEPHAPIRIN AND CEPHALOTHIN by the presence of fever. He had required vein changes at 11 and 48 hr, and had to be dropped from the study at 86 hr. The symptoms of fever, pain, tenderness, gross edema, and discoloration at the infusion site persisted for 1 week.
To demonstrate the presence of active compounds, drug concentrations in serum were determined at frequent, regular intervals throughout the study. Mean serum concentrations of both drugs were approximately 2.50,ug/ml at 6 hr and approximately 4.5 The present study in healthy volunteers demonstrates better tolerance to cephapirin than to cephalothin when the two are given by continuous intravenous infusion. Incidence, severity, and the speed with which phlebitis developed were greater with cephalothin, indicating that cephapirin may be the more useful analogue for intravenous cephalosporin therapy.
